310 related articles for article (PubMed ID: 29055841)
21. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.
Conforti F; Pala L; Sala I; Oriecuia C; De Pas T; Specchia C; Graffeo R; Pagan E; Queirolo P; Pennacchioli E; Colleoni M; Viale G; Bagnardi V; Gelber RD
BMJ; 2021 Dec; 375():e066381. PubMed ID: 34933868
[TBL] [Abstract][Full Text] [Related]
23. Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: A systematic review and meta-analysis.
Wang J; Cao L; Xu S
Int Immunopharmacol; 2020 Nov; 88():106907. PubMed ID: 33182031
[TBL] [Abstract][Full Text] [Related]
24. Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?
Cheng S; Cheung MC; Jiang DM; McDonald E; Arciero VS; Ezeife DA; Rahmadian A; Chambers A; Sabarre KA; Parmar A; Chan KKW
J Natl Compr Canc Netw; 2019 Dec; 17(12):1489-1496. PubMed ID: 31805528
[TBL] [Abstract][Full Text] [Related]
25. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
Burzykowski T; Buyse M; Piccart-Gebhart MJ; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1987-92. PubMed ID: 18421050
[TBL] [Abstract][Full Text] [Related]
27. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
[TBL] [Abstract][Full Text] [Related]
28. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis.
Li J; Gu J
Future Oncol; 2019 Nov; 15(31):3633-3646. PubMed ID: 31650854
[No Abstract] [Full Text] [Related]
30. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R
J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291
[TBL] [Abstract][Full Text] [Related]
31. Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer.
Liang F; Zhang S; Wang Q; Li W
Crit Rev Oncol Hematol; 2018 Oct; 130():36-43. PubMed ID: 30196910
[TBL] [Abstract][Full Text] [Related]
32. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study.
Kim H; Lee JE; Hong SH; Lee MA; Kang JH; Kim IH
BMC Cancer; 2019 Nov; 19(1):1100. PubMed ID: 31718585
[TBL] [Abstract][Full Text] [Related]
33. Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data.
Cartier S; Zhang B; Rosen VM; Zarotsky V; Bartlett JB; Mukhopadhyay P; Wagner S; Davis C
Oncol Res Treat; 2015; 38(3):88-94. PubMed ID: 25792079
[TBL] [Abstract][Full Text] [Related]
34. The association between antibiotics use and outcome of cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Xu H; Xu X; Wang H; Ge W; Cao D
Crit Rev Oncol Hematol; 2020 May; 149():102909. PubMed ID: 32146284
[TBL] [Abstract][Full Text] [Related]
35. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
[TBL] [Abstract][Full Text] [Related]
36. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
Ciani O; Buyse M; Garside R; Peters J; Saad ED; Stein K; Taylor RS
J Clin Epidemiol; 2015 Jul; 68(7):833-42. PubMed ID: 25863582
[TBL] [Abstract][Full Text] [Related]
37. TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials.
Lee DW; Jang MJ; Lee KH; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH; Kim TY; Han SW; Oh DY; Im SA; Kim TY
Br J Cancer; 2016 Nov; 115(10):1201-1205. PubMed ID: 27736843
[TBL] [Abstract][Full Text] [Related]
38. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.
Roviello G; Bachelot T; Hudis CA; Curigliano G; Reynolds AR; Petrioli R; Generali D
Eur J Cancer; 2017 Apr; 75():245-258. PubMed ID: 28242502
[TBL] [Abstract][Full Text] [Related]
39. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.
Kataoka K; Nakamura K; Mizusawa J; Kato K; Eba J; Katayama H; Shibata T; Fukuda H
Eur J Surg Oncol; 2017 Oct; 43(10):1956-1961. PubMed ID: 28747249
[TBL] [Abstract][Full Text] [Related]
40. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
Li L; Pan Z
Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]